Display options
Cite
Morré DJ, Hostetler B, Taggart DJ, et al. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin Proteomics. 2016;13:2doi: 10.1186/s12014-016-9103-3.
Morré, D. J., Hostetler, B., Taggart, D. J., Morré, D. M., Musk, A. W., Robinson, B. W., & Creaney, J. (2016). ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clinical proteomics, 132. https://doi.org/10.1186/s12014-016-9103-3
Morré, D James, et al. "ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms." Clinical proteomics vol. 13 (2016): 2. doi: https://doi.org/10.1186/s12014-016-9103-3
Morré DJ, Hostetler B, Taggart DJ, Morré DM, Musk AW, Robinson BW, Creaney J. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin Proteomics. 2016 Jan 22;13:2. doi: 10.1186/s12014-016-9103-3. eCollection 2016. PMID: 26807072; PMCID: PMC4724078.
Copy Download .nbib Format: NLM
Share it on

Clin Proteomics. 2016 Jan 22;13:2. doi: 10.1186/s12014-016-9103-3. eCollection 2016.

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Clinical proteomics

D James Morré, Brandon Hostetler, David J Taggart, Dorothy M Morré, A W Musk, Bruce W S Robinson, Jenette Creaney

Affiliations

  1. MorNuCo, Inc, Purdue University Research Park, 1201B Cumberland Avenue, West Lafayette, IN USA.
  2. National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia ; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia ; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia ; School of Population Health, University of Western Australia, Perth, Australia.
  3. National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia ; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia ; Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia.
  4. National Centre for Asbestos Related Disease, University of Western Australia, Perth, Australia ; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.

PMID: 26807072 PMCID: PMC4724078 DOI: 10.1186/s12014-016-9103-3

Abstract

BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicotinamide adenine dinucleotide oxidase disulfide-thiol exchanger 2 (ENOX2), a recently identified marker of malignancy, were investigated using the ONCOblot tissue of origin cancer detection test.

METHODS: Sequential serum samples collected from asbestos-exposed individuals prior to the development of frank mesothelioma were assayed for ENOX2 presence by 2-D gel immunoblot analysis to determine how long in advance of clinical symptoms mesothelioma-specific ENOX2 transcript variants could be detected.

RESULTS: Two mesothelioma-specific ENOX2 protein transcript variants were detected in the serum of asbestos-exposed individuals 4-10 years prior to clinical diagnosis of malignant mesothelioma (average 6.2 years). Either one or both ENOX2 protein transcript variants indicative of malignant mesothelioma were absent in 14 of 15 subjects diagnosed with benign pleural plaques either with or without accompanying asbestosis.

CONCLUSIONS: In a population of asbestos-exposed subjects who eventually developed malignant mesothelioma, ENOX2 protein transcript variants characteristic of malignant mesothelioma were present in serum 4-10 years in advance of clinical symptoms. As with all biomarker studies, these observations require validation in a larger, independent cohort of patients and should include prospective as well as retrospective sampling.

Keywords: Asbestos; ENOX2; Early detection; Malignant mesothelioma; ONCOblot tissue of origin cancer test; Serum analysis

References

  1. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46 - PubMed
  2. Recent Results Cancer Res. 2007;174:3-17 - PubMed
  3. Lancet. 2003 Nov 15;362(9396):1612-6 - PubMed
  4. J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 - PubMed
  5. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):748-55 - PubMed
  6. Clin Proteomics. 2014 Jan 06;11(1):2 - PubMed
  7. J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 - PubMed
  8. J Nutr. 2002 Aug;132(8 Suppl):2471S-2475S - PubMed
  9. Chest. 2007 Oct;132(4):1239-46 - PubMed
  10. Lancet. 2009 Oct 31;374(9700):1482-3 - PubMed
  11. J Clin Pathol. 2005 Mar;58(3):308-12 - PubMed
  12. N Engl J Med. 2005 Oct 13;353(15):1591-603 - PubMed
  13. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 - PubMed
  14. Biochemistry. 2007 Oct 30;46(43):12337-46 - PubMed
  15. Lung Cancer. 2001 May;32(2):197-201 - PubMed
  16. Occup Environ Med. 2008 Aug;65(8):541-3 - PubMed
  17. Int J Cancer. 1998 Jan 30;75(3):355-61 - PubMed
  18. Clin Cancer Res. 2005 May 15;11(10):3814-20 - PubMed
  19. Int J Cancer. 1998 Jan 30;75(3):362-7 - PubMed
  20. J Clin Oncol. 2003 Jul 15;21(14):2636-44 - PubMed
  21. Ann Occup Hyg. 2000 Mar;44(2):109-17 - PubMed

Publication Types